- Home
- QSI vs MLYS Comparison
QSI vs MLYS Comparison
Compare QSI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- MLYS
- Stock Information
- Founded
- QSI 2013
- MLYS 2019
- Country
- QSI United States
- MLYS United States
- Employees
- QSI N/A
- MLYS N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- MLYS Health Care
- Exchange
- QSI Nasdaq
- MLYS Nasdaq
- Market Cap
- QSI 633.2M
- MLYS 634.6M
- IPO Year
- QSI N/A
- MLYS 2023
- Fundamental
- Price
- QSI $2.54
- MLYS $9.50
- Analyst Decision
- QSI Buy
- MLYS Strong Buy
- Analyst Count
- QSI 2
- MLYS 2
- Target Price
- QSI $3.25
- MLYS $30.00
- AVG Volume (30 Days)
- QSI 60.4M
- MLYS 251.9K
- Earning Date
- QSI 02-27-2025
- MLYS 11-11-2024
- Dividend Yield
- QSI N/A
- MLYS N/A
- EPS Growth
- QSI N/A
- MLYS N/A
- EPS
- QSI N/A
- MLYS N/A
- Revenue
- QSI $2,266,000.00
- MLYS N/A
- Revenue This Year
- QSI $193.90
- MLYS N/A
- Revenue Next Year
- QSI $173.18
- MLYS N/A
- P/E Ratio
- QSI N/A
- MLYS N/A
- Revenue Growth
- QSI 232.26
- MLYS N/A
- 52 Week Low
- QSI $0.61
- MLYS $7.95
- 52 Week High
- QSI $5.77
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- QSI 52.19
- MLYS 33.43
- Support Level
- QSI $1.85
- MLYS $8.60
- Resistance Level
- QSI $5.77
- MLYS $9.97
- Average True Range (ATR)
- QSI 0.89
- MLYS 0.89
- MACD
- QSI -0.14
- MLYS -0.33
- Stochastic Oscillator
- QSI 28.38
- MLYS 18.63
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.